Therapeutic value of lymph node dissection at radical prostatectomy: A population-based case-cohort study

BJU International

Volumn 108, Issue 2, 2011, Pages 209-216

  Withrow, Diana R ^a   Degroot, Julie M ^a   Siemens, D Robert ^b   Groome, Patti A ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

case cohort study; lymph node dissection; population based; prostate cancer; prostate cancer mortality; therapeutic effect

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; GLEASON SCORE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK REDUCTION; SURVIVAL TIME; TISSUE DISTRIBUTION; TREATMENT RESPONSE;

AGED; EPIDEMIOLOGIC METHODS; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 79960016374     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09805.x     Document Type: Article

References (33)

1. Arcangeli G, Micheli A, Verna L, et al,. Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. Radiother Oncol 1995; 35: 123-8
2. Saitoh H, Hida M, Shimbo T, Nakamura K, Yamagata J, Satoh T,. Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer 1984; 54: 3078-84 (Pubitemid 15184098)
3. Briganti A, Blute M, Eastham J, et al,. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009; 55: 1251-65
4. Wagner M, Sokoloff M, Daneshmand S,. The role of pelvic lymphadenectomy for prostate cancer-therapeutic? J Urol 2008; 179: 408-13
5. Aus G, Abbou CC, Bolla M, et al,. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546-51 (Pubitemid 41278578)
6. Heidenreich A, Aus G, Bolla M, et al,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80 (Pubitemid 350166735)
7. Leissner J, Hohenfellner R, Thuroff JW, Wolf HK,. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 2000; 85: 817-23 (Pubitemid 30242784)
8. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D,. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8
9. Heidenreich A, Ohlmann CH, Polyakov S,. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007; 52: 29-37 (Pubitemid 46803038)
10. Gil-Vernet J,. Prostate cancer: anatomical and surgical considerations. BJU Int 1996; 78: 161-8 (Pubitemid 27407888)
11. Joslyn SA, Konety BR,. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006; 68: 121-5 (Pubitemid 44037727)
12. Groome PA, Rohland SL, Brundage MD, Heaton JP, Mackillop WJ, Siemens DR,. The relative risk of early death from comorbid illness among prostate cancer patients receiving curative treatment. J Urol 2005; 173: 53
13. Mackillop WJ, Zhang-Salomons J, Groome PA, Paszat L, Holowaty E,. Socioeconomic status and cancer survival in Ontario. J Clin Oncol 1997; 15: 1680-9 (Pubitemid 27167409)
14. Cox D,. Regression models and life-tables (with discussion). J R Stat Soc 1972; 34: 187-220
15. Langholz B, Jiao J,. Computational methods for case-cohort studies. Comput Stat Data Anal 2007; 51: 3737-48 (Pubitemid 46509540)
16. Chin J, Srigley J, Mayhew LA, et al,. Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management: surgical and pathological guidelines. Can Urol Assoc J 2010; 4: 13-25
17. Moynihan B,. The surgical treatment of cancer of the sigmoid flexure and rectum. Surg Gynecol Obstet 1908; 6: 463
18. Berger A, Sigurdson E, LeVoyer T, et al,. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005; 23: 8706-12 (Pubitemid 46211514)
19. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF,. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002; 167: 1295-8 (Pubitemid 34132073)
20. Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC,. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004; 172: 1840-4 (Pubitemid 39363069)
21. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H,. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170: 1872-6 (Pubitemid 37254948)
22. Klein E, Kattan M, Stephenson A, Vickers A,. How many lymphadenectomies does it take to cure one patient? Eur Urol 2008; 53: 13-5 (Pubitemid 350166738)
23. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL,. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 2001; 93: 1822-3 (Pubitemid 33150456)
24. Bochner BH, Cho D, Herr HW, Donat M, Kattan MW, Dalbagni G,. Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol 2004; 172: 1286-90 (Pubitemid 39249699)
25. Kawakami J, Meng MV, Sadetsky N, Latini DM, Duchane J, Carroll PR,. Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol 2006; 176: 1382-6 (Pubitemid 44316850)
26. Sigurdson E,. Lymph node dissection: is it diagnostic or therapeutic? J Clin Oncol 2003; 21: 965-7 (Pubitemid 46594122)
27. Pagliarulo V, Hawes D, Brands FH, et al,. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 2006; 24: 2735-42 (Pubitemid 46630570)
28. Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H, Fujisawa M,. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 2007; 13: 1192-7 (Pubitemid 46424060)
29. Briganti A, Chun FK, Salonia A, et al,. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006; 50: 1006-13 (Pubitemid 44486500)
30. Clark T, Parekh DJ, Cookson MS, et al,. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003; 169: 145-8
31. Bader P, Burkhard FC, Markwalder R, Studer UE,. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003; 169: 849-54 (Pubitemid 36188105)
32. Heidenreich A, Varga Z, Von Knobloch R,. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167: 1681-6 (Pubitemid 34240702)
33. Metcalf KS, Peel KR,. Lymphocele. Ann R Coll Surg Engl 1993; 75: 387-92 (Pubitemid 23323444)